BDA
3.5.2022 21:06:05 CEST | Business Wire | Press release
The Bermuda Business Development Agency (BDA), in partnership with the Association of Bermuda Insurers and Reinsurers (ABIR) and KBRA, is pleased to welcome climate thought leaders from around the world to Bermuda for an invite-only Bermuda Climate Summit May 23-24. The event is already at capacity, but parties interested in being added to the waitlist can email bermudaclimate@bda.bm .
The inaugural Bermuda Climate Summit will consist of an opening welcome dinner on May 23, followed by a full day of discussions on May 24, including a keynote lunch, informative panel presentations, roundtables, solutions showcase, networking opportunities, and a cocktail reception.
David Hart, BDA CEO said, “As the world’s risk capital, Bermuda is in a prime position to leverage its strengths in (re)insurance, Insurance-Linked Securities (ILS), and professional services to become the preeminent leader in climate risk finance and combat the greatest challenge of our time – climate change. Bermuda is already home to many of the world’s leading experts on weather-related catastrophes and has been working in the property catastrophe reinsurance market for decades. We are honoured to welcome global leaders to Bermuda for this extraordinary event to network, share ideas, and discuss vital solutions to the global climate crisis.”
The Hon. Walter Roban, JP, MP, Deputy Premier of Bermuda and Jim Nadler, President & CEO, KBRA will kick off proceedings by discussing Bermuda’s work in climate risk finance and how an increase in this type of financing can help mitigate against the worst effects of climate change, the benefits that innovative new technologies bring, and what a new climate finance economic pillar for Bermuda might look like.
Then John Huff, ABIR President & CEO, will moderate a panel on building resiliency in the face of climate change. Panelists include Bronwyn Claire, Senior Programme Manager, ClimateWise, Cambridge Institute for Sustainability Leadership (CISL), University of Cambridge; Ekhosuehi Iyahen, Secretary General, Insurance Development Forum; Abhisheik Dhawan, Sustainable Finance & Partnership Specialist/Corporate Lead on Climate Change, United Nations Capital Developments Fund (UNCDF); and Steven E Seitz, Director, Federal Insurance Office US Department of the Treasury.
Additional sessions will feature discussions about applied technology innovations to discuss the scale and nature of our current and anticipated climate challenges, an executive-level discussion on the growing importance of ESG and its intersection with (re)insurance and investing, and how the development of specialty financing products within the (re)insurance industry can help address climate change amid increasing consumer and regulatory pressure for climate risk management.
Guests will stay at the exclusive Rosewood Bermuda located on the shimmering waters of Bermuda’s Castle Harbour. They and their families can stay for the Bermuda Day holiday weekend to enjoy the luxury facilities and Bermuda’s many amenities including walking nature tours, twizzy tours, golf, deep-sea fishing, cave adventures, a VIP Bermuda Institute of Ocean Sciences (BIOS) tour, or a Nonsuch Island expedition. Click here to visit the BDA website for special rates and hotel information, including at the Hamilton Princess & Beach Club, conveniently located near the city of Hamilton.
The BDA thanks sponsors of Bermuda Climate Summit for their commitment to Bermuda. These include:
Partner level sponsors
- ABIR
- KBRA
Platinum sponsor
- Conduit Re
Gold sponsor
- Belco
Silver sponsor
- Aspen Re
Lanyard sponsor
- AXA XL
Beverage station sponsor
- Deloitte
Bronze sponsors
- Nephila
- HSBC Bermuda
Supporting sponsors
- Elbow Beach Capital
- Hub Culture
- KPMG
Media partner
- Bermuda Re + ILS
Click here to learn more about the BDA.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006192/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom